Godavari Drugs Ltd

Godavari Drugs has reached a new 52-week low of Rs.70.31 today, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Godavari Drugs has reached a new 52-week low of Rs.70.31, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Godavari Drugs has reached a new 52-week low of Rs.70.31, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Godavari Drugs has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The pharmaceutical microcap’s recent assessment highlights a cautious stance driven by subdued sales growth, persistent negative earnings, and bearish trading patterns.

Godavari Drugs has reached a new 52-week low of Rs.72.11, marking a significant decline in its stock price amid a challenging market environment and subdued financial performance over the past year.

Godavari Drugs has reached a new 52-week low of Rs.73.2, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market factors that have influenced its performance.

Godavari Drugs has reached a new 52-week low of Rs.74, marking a significant milestone in its ongoing price decline. The stock’s performance over the past year reflects a challenging period for the company within the Pharmaceuticals & Biotechnology sector.

Godavari Drugs has reached a new 52-week low of Rs.74, marking a significant milestone in its ongoing price decline. This development reflects a continuation of the stock’s subdued performance over the past year, contrasting with broader market gains.

Godavari Drugs has reached a new 52-week low of Rs.74, marking a significant milestone in its recent price movement. This decline reflects ongoing pressures on the stock within the Pharmaceuticals & Biotechnology sector, as it trades below all key moving averages amid broader market gains.

Godavari Drugs has reached a new 52-week low of Rs.75.2, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Godavari Drugs has reached a new 52-week low, with its share price touching Rs.75.45 today. This marks a significant decline for the pharmaceutical company amid broader market fluctuations and sectoral pressures.

Godavari Drugs has reached a new 52-week low of Rs.77.01 today, marking a significant decline amid a sustained downward trajectory over recent sessions. The stock’s performance contrasts sharply with broader market trends, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Godavari Drugs, a player in the Pharmaceuticals & Biotechnology sector, touched a fresh 52-week low of Rs.77.01 today, marking a significant milestone in its recent price movement. The stock has been on a declining trajectory over the past three sessions, reflecting a cumulative return of -7.1% during this period.

Godavari Drugs has reached a new 52-week low of Rs.78.06 today, marking a significant decline as the stock continues to trade below all key moving averages amid a challenging market environment.

Godavari Drugs has reached a new 52-week low of Rs.78.06 today, marking a significant point in its recent price trajectory as the stock continues to trade below all major moving averages amid a challenging market environment.

Godavari Drugs, a player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.78.25 on 19 Nov 2025, marking a significant decline in its stock price amid ongoing subdued financial performance and market pressures.

Godavari Drugs Ltd., a Nanded-based manufacturer of active pharmaceutical ingredients (APIs) and drug intermediates, reported a net profit of ₹1.00 crore for Q2 FY26, marking a modest sequential decline of 3.85% from ₹1.04 crores in Q1 FY26, whilst registering a sharp year-on-year contraction of 8.26% from ₹1.09 crores in Q2 FY25. With a market capitalisation of just ₹62.00 crores, this micro-cap pharmaceutical player continues to grapple with margin pressures and tepid revenue growth, raising serious concerns about its ability to navigate an increasingly competitive API landscape.